ArticleMultiple sclerosis and related disorders2021

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.

Barbara Barun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.